CTLA4 and melanoma: We next performed transcriptomic profiling of publicly available RNA-Seq data from a previously described patient cohort (n=73) with malignant melanoma undergoing ICI immunotherapy with either anti-PD-1 or its combination with anti-CTLA-4.9